Psychological outcomes associated with anemia-related fatigue in cancer patients.
This article examines the relationships between chemotherapy-induced anemia, fatigue, and psychological distress among anemic cancer patients with solid tumors. Patients participating in two randomized clinical trials evaluating the efficacy of darbepoetin alfa (Aranesp) completed a questionnaire at baseline, at the beginning of each chemotherapy cycle, and at the end of the 12-week treatment period. The questionnaire included four psychological distress outcomes: Brief Symptom Inventory (BSI) Depression and Anxiety, Functional Assessment of Cancer Therapy (FACT)-Emotional Well-Being, numeric rating scale of Overall Health, and the FACT-Fatigue subscale. Patients with a hemoglobin response of at least a 2 g/dL increase were more likely to experience meaningful improvements (at least 3 points) in FACT-Fatigue scores than nonresponders (55.0% vs 39.8%; P = .0004). Patients with meaningful improvements in FACT-Fatigue scores reported significantly greater improvements in each of the psychological outcomes relative to those without improved fatigue (P <.0001). For BSI Depression and Anxiety, the differences in mean change scores between patients with and without improved fatigue were 8.2 and 7.7, respectively. Improving the hemoglobin levels of patients undergoing chemotherapy and suffering from anemia-related fatigue has the potential to produce significant positive effects on patients' fatigue, depressive symptoms, anxiety, feelings of helplessness, and overall health.
Kallich
Joel D
JD
Health Economics and Epidemiology, Amgen, Inc., Thousand Oaks, California 91320-1799, USA. jkallich@amgen.com
Tchekmedyian
N Simon
NS
Damiano
Anne M
AM
Shi
Jinhai
J
Black
Jeanne T
JT
Erder
M Haim
MH
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005221:Fatigue / Q000209:etiology / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000209:etiology / Q000503:physiopathology*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D011788:Quality of Life
D000970:Antineoplastic Agents; D004921:Erythropoietin; D000068256:Darbepoetin alfa